Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Plos One|May 22, 2019
Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in miceTimothy Affolter, Heather P Llewellyn, Derek W Bartlett, et al.
Molecular Pharmacology|March 30, 2007
CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptorChanghua Ji, Jun Zhang, Marianna Dioszegi, et al.
Pharmaceutical Research|September 26, 2013
Pharmacokinetics and pharmacodynamics of CD4-anchoring bi-functional fusion inhibitor in monkeysXingrong Liu, Ying C Ou, Jun Zhang, et al.
Virology Journal|May 3, 2008
Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1Erhard Kopetzki, Andreas Jekle, Changhua Ji, et al.
Antiviral Research|June 30, 2009
CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potencyAndreas Jekle, Eugene Chow, Erhard Kopetzki, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|May 16, 2024
Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumorsJialin Zhang, Gengshen Yin, Chunmiao Ye, et al.
Proteomics. Clinical Applications|June 23, 2015
Identification of six cell surface proteins for specific liver targetingAxel Ducret, Sabine Kux van Geijtenbeek, Daniel Röder, et al.
Plos One|February 5, 2024
Pharmacokinetics, pharmacodynamics, and toxicity of a PD-1-targeted IL-15 in cynomolgus monkeysChanghua Ji, Bing Kuang, Bernard S Buetow, et al.
Bioorganic & Medicinal Chemistry Letters|July 21, 2010
Exploration of a new series of CCR5 antagonists: multi-dimensional optimization of a sub-series containing N-substituted pyrazolesRémy C Lemoine, Ann C Petersen, Lina Setti, et al.
Pageof 5